Cardiovascular Considerations of Remdesivir and Favipiravir in the Treatment of COVID-19.

Q2 Medicine

Cardiovascular and Hematological Disorders - Drug Targets Pub Date : 2021-01-01 DOI:10.2174/1871529X21666210812103535

Mohammad Amin Shahrbaf, Mohammadreza Tabary, Isa Khaheshi

引用次数: 4

Abstract

After the outbreak of COVID-19, many novel drugs have been introduced to improve patients' conditions. Remdesivir and Favipiravir are among the most common drugs used against SARS-CoV-2. Although promising, cardiovascular side effects of these drugs should be considered by physicians and nurses. In this study, we searched databases for assessing the cardiovascular side effects of Remdesivir and Favipiravir. It seems that despite the beneficial effects of these drugs, due to the cardiovascular complications of COVID-19 and cardiovascular side effects of these drugs, which can overlap with each other, the use of these drugs can be a challenging issue in the cardiovascular practice.

查看原文本刊更多论文

瑞德西韦和法匹拉韦治疗COVID-19对心血管的影响

新冠肺炎疫情爆发后，许多新药被引入，以改善患者的病情。Remdesivir和Favipiravir是对抗SARS-CoV-2最常用的药物。虽然有希望，但这些药物的心血管副作用应该被医生和护士考虑。在这项研究中，我们检索了数据库以评估Remdesivir和Favipiravir的心血管副作用。尽管这些药物有有益的作用，但由于COVID-19的心血管并发症和这些药物的心血管副作用可能相互重叠，这些药物的使用在心血管实践中可能是一个具有挑战性的问题。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cardiovascular and Hematological Disorders - Drug Targets Medicine-Cardiology and Cardiovascular Medicine

CiteScore

1.90

自引率

0.00%

发文量

期刊介绍： Cardiovascular & Hematological Disorders - Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular targets involved in cardiovascular and hematological disorders e.g. disease specific proteins, receptors, enzymes, genes. Each issue of the journal contains a series of timely in-depth reviews written by leaders in the field covering a range of current topics on drug targets involved in cardiovascular and hematological disorders. As the discovery, identification, characterization and validation of novel human drug targets for cardiovascular and hematological drug discovery continues to grow.